Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04396808Not ApplicableActive Not Recruiting

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

Role: collaborator

NCT04167332Not Yet Recruiting

Prospective Collection of Samples for Urothelial Cancer of Bladder

Role: collaborator

NCT03122964Unknown

Multi Institutional Study in Patient Presenting With Hematuria

Role: lead

NCT03082274Unknown

Prospective Validation of Prostate Biomarkers for Repeat Biopsy

Role: lead

NCT02250313Terminated

PASCUAL (Prostate Assay Specific Clinical Utility at Launch) Study

Role: lead

All 5 trials loaded